Table 2.
Univariable und multivariable Cox regression models predicting progression-free survival (PFS; A) and overall survival (OS; B) in first- and second-line metastatic castration resistant prostate cancer (mCRPC) according to treatment with 177-Lutetium prostate-specific membrane antigen radioligand therapy (Lu-PSMA) vs. androgen receptor pathway inhibitor (ARPI) or docetaxel chemotherapy
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| PFS | HR | CI | p value | HR | CI | p value |
| ARPI | Ref | - | - | Ref | - | - |
| Lu-PSMA* | 0.70 | 0.43–1.14 | 0.16 | 0.24 | 0.06–0.97 | 0.045 |
| Docetaxel | Ref | - | - | Ref | - | - |
| Lu-PSMA* | 0.48 | 0.28–0.82 | < 0.01 | 0.86 | 0.18–4.00 | 0.8 |
| OS | HR | CI | p value | HR | CI | p value |
| ARPI | Ref | - | - | Ref | - | - |
| Lu-PSMA+ | 0.64 | 0.32–1.30 | 0.22 | 0.065 | 0.01–0.62 | 0.01 |
| Docetaxel | Ref | - | - | Ref | - | - |
| Lu-PSMA+ | 0.34 | 0.17–0.72 | < 0.01 | 0.03 | 0.01–0.30 | < 0.01 |
Abbreviation: HR, Hazard Ratio; CI, Confidence interval; ECOG, Eastern Cooperative Oncology Group
*Age at metastatic disease, Gleason Score, ECOG status, metastatic sides at mCRPC, year of treatment
+Age at metastatic disease, Gleason Score, ECOG status, metastatic sides at mCRPC, number of systemic treatments for mCRPC, year of treatment